Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
Richard P. Tobin(Society of Surgical Oncology), Martin D. McCarter(University of Colorado Cancer Center), Karl D. Lewis(University of Colorado Denver), Kimberly R. Jordan(University of Colorado Anschutz Medical Campus), William A. Robinson(University of Colorado Anschutz Medical Campus), Virginia F. Borges(University of Colorado Anschutz Medical Campus), Dana M. Davis(Dalhousie University), René González(University of Miami)
Cited by 198
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k